Luspatercept

罗特西普

Report date: 2026/05/06 20:02:28
First In Class

Base Information

Drug NameLuspatercept
Drug Alias NameLuspatercept-aamtReblozyl利布洛泽RebrozylACE-536 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTransforming growth factor beta inhibitors
TargetsTransforming growth factor beta
Therapy Area/IndicationsCytopeniaNeutropeniaLeukopenia +[16] 
Global Approved IndicationsMyelodysplastic Syndromesbeta-ThalassemiaAnemia
Approved Indications in Chinabeta-Thalassemia
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/08
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAcceleron Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesZhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, ChinaBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co Ltd +[13] 
Inactive CompaniesSharp CorpThe University Of Texas MD Anderson Cancer Center
Active IndicationsCytopeniaNeutropeniaLeukopenia +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeB03XA06
Related LinksWikipediaDrugBankKEGG